US Pharma MarketingSamsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).
Source: Pharmaceutical Technology